Researchers from the University of Oxford have today released their findings about the so-called \u2018correlates of protection\u2019 against symptomatic COVID-19; potentially a tool to speed up safe development of new vaccines which may assist regulators in assessing the likely potency of any new COVID-19 vaccine without the need for Phase III efficacy trial data.
A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.
Andrew Pollard, Director of the Oxford Vaccine Group, and Professor of Paediatric Infection and Immunity, becomes a Knight Bachelor for services to Public Health, particularly during the COVID-19 Pandemic.
For the one in ten who say they won\u2019t take a COVID-19 vaccine, messaging that focuses on personal rather than collective benefits is more effective.
Research, from Com-COV study comparing mixed dosing schedules of Pfizer / Oxford-AstraZeneca vaccines, shows increase in the frequency of mild-moderate symptoms in those receiving either mixed dosing schedule. Adverse reactions were short-lived, with no other safety concerns. Impact of mixed schedules on immunogenicity unknown as yet, with data to follow from this study.
Dr Samantha Vanderslott and Dr Seilesh Kadambari discuss their collaborative approach to providing ethnic minority groups with information on vaccines.
Early diagnosis is of primary importance both to obtain the best effect of innovative medications and to accelerate their development, writes Professor Laurent Servais.
Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.
Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.
Medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.
Our partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.
- Oxford-AstraZeneca coronavirus vaccine 79% effective against symptomatic COVID-19 overall \r\n- Vaccine 100% effective against severe or critical symptomatic COVID-19 \r\n- No safety concerns reported
Associate Professor Andi Roy leads one of the five research teams across the UK that have been awarded the 2021 Cancer Research UK-Children with Cancer UK Innovation Award. The awards, which provide a total of \u00a34.3 million in scientific funding, will allow leading researchers in the field to delve into the biology of children\u2019s and young people\u2019s cancers, with the hope of finding new ways to prevent and treat these complex cancers.
Four academics supported by the NIHR Oxford Biomedical Research Centre have been awarded a prestigious national award, among them Matthew Snape from the Oxford Vaccine Group.
The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.
The University of Oxford, together with three partner sites in London, Southampton and Bristol, is to launch the first study to assess the safety and immune responses in children and young adults of the ChAdOx1 nCoV-19 coronavirus vaccine.
![](\"https://www.paediatrics.ox.ac.uk/news/oxford-researchers-identify-levels-of-antibody-protection-required-to-prevent-symptomatic-covid-19/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n